Karo Bio Announces That Merck & Co., Inc. Plans To Proceed With Phase II Clinical Evaluation Of Candidate Compound

The Swedish biotech company Karo Bio (Reuters: KARO.ST) announced that Merck & Co., Inc., through an affiliate, plans to enter a clinical phase IIa trial with the collaboration’s lead investigational drug candidate, MK-6913, identified as part of their joint research collaboration. No milestone payment to Karo Bio is associated with the initiation of phase II clinical development.

Merck's Gardasil Effective At Preventing HPV, Cervical Disease In Older Women, Study Finds

Merck’s human papillomavirus vaccine, Gardasil, was 90% effective in preventing infection with the virus and cervical disease in women ages 24 to 45, according to a study published Monday in the medical journal Lancet,

« Previous Page